alexa Scientific Research

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Scientific Research

Pi3k Pathway-Specific Inhibitors: New Hope for Patients with Er-Positive or Her2-Positive Breast Cancers

Identify genes/proteins dysregulated in different subset of breast cancers (especially ER+ and HER2+ breast cancers include all of the intrinsic molecular subtypes) and dissecting their signaling pathways for novel/combinatorial therapeutic intervention.Try to identifying a “signaling hub” as an enticing molecular target for subset-specific breast cancer therapy and overcome conventional targeted therapy resistance (like trastuzumab for HER2+ patients and tamoxifen or aromatase inhibitor for ER+ patients), with the intent to translate these important findings into future clinical trials.In particular, we are studying the role of aberrantly activated signaling pathways, such as PI3K-AKT-mTOR and RAS-MAPK pathways, as potential therapeutic targets in subset-specific breast cancers.


  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger